Skip to main content
Premium Trial:

Request an Annual Quote

Expression Analysis Starts Providing Sequencing Services on PacBio RS

Premium

Genomics service provider Expression Analysis said this week that it has begun offering sequencing services on Pacific Biosciences' single-molecule sequencing platform.

The company, based in Durham, NC, said it is the first commercial provider offering services on the PacBio RS system in the US.

According to EA, first applications for the PacBio RS include de novo and hybrid genome assemblies, pathogen identification, and targeted resequencing. The company said it has already lined up several sequencing projects, including viral and bacterial sequencing studies with a large undisclosed pharmaceutical client and with academic institutions and plant and animal studies with government and commercial organizations.

PacBio is recommending EA as its North American service provider for the pharmaceutical market. "Given their deep expertise working with new and emerging genomic technologies and the world's leading pharmaceutical companies, EA is a natural fit to be our recommended commercial partner for providing sequencing services to the drug discovery and development market," said Pat Brooks, vice president of sales at PacBio, in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.